ReviewEngineering in life sciences2018
Silica-based organic-inorganic hybrid nanoparticles and nanoconjugates for improved anticancer drug delivery.
Review in Engineering in life sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 51 citations in OpenAlex.
- Integrating diagnosis and therapy in hepatocellular carcinoma: advances in nanotheranostics.Frontiers in bioengineering and biotechnology · 2026Review
- Advances in Mesoporous Silica and Hybrid Nanoparticles for Drug Delivery: Synthesis, Functionalization, and Biomedical Applications.Pharmaceutics · 2025Review
- Nanomedicine for chronic pain management: From pathophysiology to engineered drug delivery systems.Materials today. Bio · 2025Review
- Optical Properties and Antimicrobial Activity of Si/PVP Hybrid Material Combined with Antibiotics.Molecules (Basel, Switzerland) · 2024Article
- Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges.Drug delivery and translational research · 2024Review
- Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment-A Recent Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Molecularly Targeted Fluorescent Sensors for Visualizing and Tracking Cellular Senescence.Biosensors · 2023Review
- Oxygen and Drug-Carrying Periodic Mesoporous Organosilicas for Enhanced Cell Viability under Normoxic and Hypoxic Conditions.International journal of molecular sciences · 2022Article
- Modern Nanocarriers as a Factor in Increasing the Bioavailability and Pharmacological Activity of Flavonoids.Applied biochemistry and microbiology · 2022Article
- Synthesis of Resveratrol Loaded Hybrid Silica-PAMAM Dendrimer Nanoparticles With Emphases on Inducible Nitric Oxide Synthase and Cytotoxicity.Plant foods for human nutrition (Dordrecht, Netherlands) · 2021Article
- Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management.Biomedicines · 2020Review
- Indocyanine Green Loaded Modified Mesoporous Silica Nanoparticles as an Effective Photothermal Nanoplatform.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the introduction of first generation MSNs for drug delivery with some challenges such as large particle sizes, irregular morphologies and aggregations, second generation provided uniform spherical morphologies, tunable pore/particle sizes and compositions. Henceforth, organic-inorganic hybrid mesoporous silica nanosystems have grown rapidly and utilized for active and passive targeting of tumorigenic cells especially conjugated with organic polymers followed by third generation counterparts with improved functionalities for cancer therapy. The aim of this review article is to focus on the advancements in mesoporous silica based organic-inorganic hybrid nanoparticles developed as drug carriers targeting cancer cells. Brief introduction to the state-of-the-art in passive and active targeting methods is presented. Specifically, therapeutic, diagnostic and theranostic applications are discussed with emphases on triggered and ligand conjugated organic-inorganic hybrid mesoporous silica nanomaterials. Although mesoporous silica nanoparticles perform well in preclinical tests, clinical translation progresses slowly as appropriate doses needs to be evaluated for human use along with biocompatibility and efficiency depending on surface modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.